Ocular Coherence Tomography Supports an Investigational New Drug Application for a C3 Complement Inhibitor Targeting Macular Degeneration (SOT 2023) - Apellis Medical Hub Canada

Ocular Coherence Tomography Supports an Investigational New Drug Application for a C3 Complement Inhibitor Targeting Macular Degeneration

Share Via Email

Back to Conference Resources

GA Congress Presentations Society of Toxicology (SOT) 2015

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.